ACRO Biomedical develops a proprietary SCCO2 extraction technology to remove cells, fatsnon-collagenous proteins from animal tissuesorgans, leaving the intact collagen scaffolds as biomaterials for tissue engineering. This technology is applied on porcine cornea to develop Collagen Ophthalmic Matrix for corneal transplantation, which is entering human clinical trials, in hoping to serve as an alternative solution to human donated cornea.

ACRO＇s Collagen Ophthalmic Matrix is the first product to apply the SCCO2 decellularization technology for the completely removal of the cells from porcine cornea without using any chemical detergent. The natural collagen scaffold structure is retained undamaged for corneal repair. The success of this corneal tissue decellularization process is a pioneering work in Taiwan＇s biotechnology community

ACRO Biomedical provides the best natural scaffold for cell to attach, grow,differentiate. Collagen Ophthalmic Matrix will soon enter clinical trial phase, which is the last challenge before entering the market. When launching the product to the market, the shortage of the human donated cornea, the long waiting time,the rejection reaction will no longer exist.